CLSD News and Press, Clearside Biomedical Inc. From 12/14/23

- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector ® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14...

2023-11-13 19:18:08 ET Clearside Biomedical, Inc. (CLSD) Q3 2023 Results Conference Call November 13, 2023 04:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call Participants Serge Belanger - Need...

2023-11-13 16:10:45 ET More on Clearside Biomedical BioCryst, Clearside Biomedical in pact for diabetic eye disease Seeking Alpha’s Quant Rating on Clearside Biomedical Historical earnings data for Clearside Biomedical Financial information for Clearsi...

- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, a...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Clearside Biomedical Inc. (CLSD) is expected to report $-0.16 for Q3 2023

ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D.,...

ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral and poster present...

2023-11-03 12:59:13 ET More on BioCryst, Clearside Biomedical, etc. BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stock's Bear Run Clearside Biomedical, Inc. (CLSD) Q2 2023 Earnings Call...

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- ...